Oversight Committee of the Cancer Prevention and Research Institute of Texas Meeting Minutes
The committee reviewed reports from the CEO, Chief Scientific Officer, Chief Product Development Officer, and Chief Compliance Officer regarding grant award recommendations for academic research and product development programs. Key discussions included appointment approvals for various advisory committees, the adoption of an honoraria policy, the approval of health and safety code waivers, and proposed rule amendments. Additionally, the committee reviewed internal auditor reports, grant management platform modernization updates, and authorized the disbursement of grant funds via advance payments. Financial matters, including the operating budget, bond issuance resolutions, and legislative appropriations requests for the 2028-2029 biennium, were also addressed.
Enterprise
Get verified public-sector contacts at scale
Find verified emails, direct dials, role context, job-change updates, and organization signals across every public-sector account you sell to.
The committee meeting covered a wide range of administrative, compliance, and programmatic topics. These included CEO, compliance, scientific, and product development officer reports, alongside recommendations for academic research and product development grant awards. Discussions also encompassed the appointment of members to various advisory and scientific research committees, proposed amendments to administrative rules, financial status updates, legislative appropriation requests, and bond issuance resolutions. Additionally, the committee addressed internal audit reports, compliance training, and preparations for upcoming conferences.
Aug 20, 2025·Board meeting
Oversight Committee Meeting
The meeting included reports from the CEO, Chief Compliance Officer, Chief Scientific Officer, Interim Chief Prevention Officer, and Chief Product Development Officer. Key discussion points included FY 2025 grant funds, personnel updates, the 89th Legislative Session, grantee reports, compliance attestations, and grant award recommendations for various programs. The committee also addressed appointments to scientific research and prevention programs, the FY 2026 honoraria policy, advisory committee appointments, and presentations. Additionally, the committee discussed health and safety code waivers, the chief financial officer's report, contract approvals, internal auditor reports, the 2026 CPRIT Innovations VII Conference, grant management platform modernization assessment, communications updates, subcommittee business, election of board officers, and future meeting dates.
